At an investor update at the end of last week, Lonza has announced its "One Lonza" restructuring strategy, which aims to reorganize its CDMO business, simplify its...
Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest...
Swiss contract development and manufacturing organization (CDMO) Lonza has announced a long-term extension of its collaboration with a key global biopharmaceutical...
Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was...
Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule...
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine...
